Roche Holding AG
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
Study of Therapeutic Monitoring of Mycophenolate Mofetil (MMF/CellCept) After Kidney Transplantation
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2004-07-14
- Last Posted Date
- 2016-11-06
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 720
- Registration Number
- NCT00087581
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With Ribavirin in Patients With Chronic Hepatitis C (CHC) Previously Treated With PEG-Intron + Ribavirin
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2004-07-14
- Last Posted Date
- 2016-06-08
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 57
- Registration Number
- NCT00087568
REPEAT Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Therapy in Combination With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Who Did Not Respond to Previous PegIntron (Peginterferon Alfa-2b (12KD))/Ribavirin Combination Therapy
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2004-07-14
- Last Posted Date
- 2016-01-14
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 948
- Registration Number
- NCT00087646
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With Copegus (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Enrolled in a Methadone Maintenance Treatment Program.
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2004-07-14
- Last Posted Date
- 2016-03-04
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 48
- Registration Number
- NCT00087594
A Study of Capecitabine In Combination With Docetaxel vs Capecitabine Followed by Docetaxel As First-Line Treatment For Metastatic Breast Cancer
Phase 4
Terminated
- Conditions
- First Posted Date
- 2004-07-14
- Last Posted Date
- 2017-02-03
- Lead Sponsor
- Hoffmann-La Roche
- Registration Number
- NCT00087620
PHOENIX Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) and COPEGUS (Ribavirin) Administered After Liver Transplantation for Hepatitis C.
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2004-07-14
- Last Posted Date
- 2018-03-29
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 115
- Registration Number
- NCT00087633
Peak Study - A Study of Pegasys (Peginterferon Alfa-2a (40KD)) in Combination With Copegus (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC).
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2004-07-14
- Last Posted Date
- 2016-07-01
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 385
- Registration Number
- NCT00087607
Paclitaxel and Capecitabine in Treating Women With Metastatic Breast Cancer
Phase 2
Completed
- Conditions
- First Posted Date
- 2004-04-28
- Last Posted Date
- 2017-08-16
- Lead Sponsor
- Hoffmann-La Roche
- Registration Number
- NCT00005649
- Locations
- 🇺🇸
PPD Development, Wilmington, North Carolina, United States
A Study of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis Previously Treated With Bonviva
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2004-04-21
- Last Posted Date
- 2017-07-14
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 719
- Registration Number
- NCT00081653
A Study of Mircera in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2004-04-16
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 324
- Registration Number
- NCT00081471
© Copyright 2024. All Rights Reserved by MedPath